In July 2004, Aspira Biosystems Inc was acquired by Nanomune Technologies, Inc and has not been SBIR since then. Aspira Biosystems is developing advanced capture agents and protein biochips for predictable proteomics. Our products are based on a unique patent-pending platform technology, called ProteinPrintTM, which enables sequence-based separation and high-throughput analysis of known and unknown proteins. Aspira's ProteinPrint technology represents a major breakthrough for the biopharmaceutical industry. Protein research and drug discovery laboratories that have identified proteins of interest using gel electrophoresis, high-throughput gene analyses or database searches can rapidly obtain highly specific capture agents for target validation and high-throughput screening
